U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710664) titled 'A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region' on July 13.

Brief Summary: This is an open-label, single-center, investigator-initiated exploratory trial evaluating NWRD09 in 10 participants with persistent HPV16 infection in the anal region.

Study Start Date: July 20

Study Type: INTERVENTIONAL

Condition: Persistent HPV16 Infection

Intervention: DRUG: NWRD09

Each participant will be administered NWRD09 by IM injection

Recruitment Status: RECRUITING

Sponsor: Newish Biotech (Wuxi) Co., Ltd.

Disclaimer: Curated by HT Syndication....